[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"circadian-dysregulation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:circadian-dysregulation":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,71,99,134,158,236],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100260801","ocean-registry-obesity-and-clock-for-elegant-aging-registry-100260801",false,"NCT02674230","OCEAN Registry: Obesity and Clock for Elegant Aging Registry","OCEAN Registry: Obesity and Clock for Elegant Aging Registry 肥胖控制及生理時鐘之研究計畫","OCEAN","Inclusion Criteria:\n\n* Age ≥ 20 years old\n* Body mass index ≥ 24 kg\u002Fm2\n* For normal subjects, Body mass index \\\u003C 24 kg\u002Fm2\n\nExclusion Criteria:\n\n* No inform consent\n* Use of steroid medications\n* Severe systemic diseases or organ failure with estimated life expectancy of 6 months or less",true,"ALL","20 Years",{"count":21,"type":22},2000,"ESTIMATED","10 Years","OBSERVATIONAL","This study aims to study the relationships between obesity, circadian rhythm, and aging. The investigators set up a prospective cohort registry for morbid obesity, obesity, and normal subjects with annual follow-up. The cohort aims to investigate the pathophysiological, molecular, genetic, and cellular aspects of the relationships between obesity, circadian deregulation, and impacts on aging. Clinical data, questionnaires, biological material, and molecular signatures will be collected and investigated.",[27,28,29,30],"Obesity","Circadian Dysregulation","Aging","Cardiovascular Disease","RECRUITING","2026-06-18",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":4},"2011-07",{"date":39,"type":22},"2035-06",{"name":41,"class":42},"Chang Gung Memorial Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":18,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100622512","feasibility-of-light-therapy-in-the-pediatric-intensive-care-unit-icu-100622512","NCT07384585","Feasibility of Light Therapy in the Pediatric Intensive Care Unit (ICU)","Feasibility of Light Therapy in the Pediatric ICU","Inclusion Criteria:\n\n* Anticipated to remain admitted to the study hospital pediatric ICU for additional 48 hours\n* English-speaking parent\u002Flegally authorized representative available at the bedside\n\nExclusion Criteria:\n\n* Patients unable to open their eyes to receive light therapy (Glasgow Coma Scale eye opening score of 1 or neuromuscular blockade)\n* Patients with contraindications to light therapy (e.g., migraines, retinal disease, diseases associated with retinal complications, blindness, bipolar disorder, seizure disorder, traumatic brain injury)\n* Suspected\u002Fidentified neglect\u002Fabuse, Child Protective Services involvement, or ward of state\n* Children receiving palliative\u002Fend-of-life care\n* Unable to fit light box\u002Fcart in patient room","4 Years","17 Years",{"count":54,"type":22},30,"INTERVENTIONAL",[57],"NA","The goal of this clinical trial is to understand how easy or difficult it is for critically ill children (4-17 years old) to have light therapy while in the pediatric ICU. Participants will have a light meter at their bedside to measure light levels. Each morning, a light box will be placed at their bedside. Children, family, and staff will be asked to completed feedback surveys regarding the light therapy. Study participation will continue for a maximum of 5 days.",[28,60,61],"Light Exposure","Pediatric Critical Illness","2026-05-20",{"date":64,"type":35},"2026-05-22",{"date":66,"type":35},"2026-03-26",{"date":68,"type":22},"2027-01",{"name":70,"class":42},"Laura Beth Kalvas",{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":17,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":43},"100628294","body-clocks---coordination-of-peripheral-and-central-oscillators-100628294","NCT07459764","Body Clocks - Coordination of Peripheral and Central Oscillators","Confluence of Sleep, Circadian Rhythms, and the Menstrual Cycle on Injury Risk in Women","Inclusion Criteria:\n\n* Regular menstrual cycle (21-35 days)\n* 18-30 years old\n\nExclusion Criteria:\n\n* Neuromuscular or neurodegenerative disease\n* Gut disorders\n* circadian sleep disorders\n* prescription medications affecting sleep\n* recovering from physical injury\n* taking hormonal birth control","FEMALE","18 Years","30 Years",{"count":82,"type":22},20,"The investigators are conducting an observational trial examining young women over the course of 28 days in which we are monitoring movement, sleep, heart rate, oxygen saturation, gut physiology, light, and menstrual cycle. The inter- and independence of the cyclicity of these variables with each other, the circadian cycle, the menstrual cycle, and the sleep cycle will be tested.",[28],[86,87,88,89],"sleep","circadian","menstrual","women's health","2026-04-21",{"date":92,"type":35},"2026-04-24",{"date":94,"type":35},"2026-04-15",{"date":96,"type":22},"2026-09-30",{"name":98,"class":42},"Stanford University",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":17,"sex":18,"minAge":79,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":55,"phases":110,"briefSummary":111,"conditions":112,"keywords":122,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":43},"100618258","nighttime-synchrony-of-your-nutrition-and-circadian-health-100618258","NCT07329283","Nighttime Synchrony of Your Nutrition and Circadian Health","Nighttime Synchrony of Your Nutrition and Circadian Health: The N-Sync Study","N-Sync","Inclusion Criteria:\n\n1. Age: 18-35 years old; equal numbers of men and women\n2. Body Mass Index (BMI): 18.5-24.9 kg\u002Fm2\n3. Sleep Habits: habitual self-reported average total sleep time (TST) 7-9 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or apnea hypopnea index (AHI) ≥5\n2. Evidence of significant organ system dysfunction or disease (e.g., heart disease, diabetes)\n3. Fasting plasma glucose ≥100 mg\u002FdL\n4. Major psychiatric illness (e.g., major depressive disorder)\n5. Cancer that has been in remission less than 5 years\n6. History of shift-work in prior year\n7. Weight change \\>5% of body weight over prior six months\n8. Currently following a weight-loss program\n9. Menopause\n10. Pregnant\u002Fnursing\n11. Greater than 5-day variation in menstrual cycle length month-to-month\n12. Currently smoking\n13. Alcohol intake \\>14 drinks\u002Fweek or \\>3 drinks\u002Fday.\n14. Use of prescription medications (except oral contraceptives) within one month prior to or during in-lab visits.\n15. Consumption of illegal drugs or \\>500mg per day of caffeine.","35 Years",{"count":109,"type":22},120,[57],"Sleep is an important factor for overall health. This study will see how different light exposure patterns and food intake impact a person's metabolism (how the body breaks down food) when sleeping is reduced.\n\nParticipants will attend 6 to 8 in-person visits to the study clinic, including three overnight stays. People will complete surveys and medical tests. The study will last about 4 to 6 months.",[113,114,115,116,117,118,119,120,121,28,60],"Sleep","Metabolism Changes","Circadian Rhythm","Lifestyle Factors","Sleep Hygiene","Sleep Hygiene, Inadequate","Sleep Deprivation","Insufficient Sleep","Circadian Misalignment",[113,60,123,115,124,116,117],"Metabolism","Food Intake","2026-01-20",{"date":127,"type":35},"2026-01-22",{"date":129,"type":35},"2025-12-19",{"date":131,"type":22},"2031-05-31",{"name":133,"class":42},"University of Utah",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":17,"sex":18,"minAge":141,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":55,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":43},"100515061","niaimproving-function-and-well-being-by-improving-patient-memory-transdiagnostic-sleep-and-circadian-treatment-100515061","NCT05986604","NIA_Improving Function and Well-being by Improving Patient Memory: Transdiagnostic Sleep and Circadian Treatment","NIA_Improving Sleep and Circadian Functioning, Daytime Functioning, and Well-being for Midlife and Older Adults by Improving Patient Memory for a Transdiagnostic Sleep and Circadian Treatment","Inclusion criteria:\n\n1. Aged 50 years and older;\n2. English language fluency;\n3. Experiencing a mobility impairment;\n4. Low income;\n5. Exhibit a sleep or circadian disturbance as determined by endorsing 4 \"quite a bit\" or 5 \"very much\" (or the equivalent for reverse scored items) on one or more PROMIS-SD questions.\n6. 25-30 on the Montreal Cognitive Assessment, as a negative screen for cognitive impairment.\n7. Able\u002Fwilling to give informed consent.\n\nExclusion criteria:\n\n1. Severe untreated sleep disordered breathing (AHI\\>30) or moderate untreated sleep disordered breathing with severe daytime sleepiness (AHI of 15-30 and Epworth Sleepiness Scale \\>10);\n2. Medical conditions that prevent a participant from comprehending and following the basic tenants of treatment (e.g., dementia) or that interfere with sleep in a manner that can't be addressed by a cognitive behavioral treatment (e.g., the Structured Clinical Interview for Sleep Disorders will be used to screen for narcolepsy, REM sleep behavior disorder) or that may preclude full participation (e.g., receipt of end of life care);\n3. Homelessness;\n4. Night shift work \\>2 nights per week in the past 3 months;\n5. Substance abuse\u002Fdependence only if it makes participation in the study unfeasible;\n6. Suicide risk sufficient to preclude treatment on an outpatient basis.","50 Years",{"count":143,"type":22},178,[57],"Mental illness is often chronic, severe, and difficult to treat. Though there has been significant progress towards establishing effective and efficient interventions for psychological health problems, many individuals do not gain lasting benefits from these treatments. The Memory Support Intervention (MSI) was developed utilizing existing findings from the cognitive science literature to improve treatment outcomes. In this study, the investigators aim to conduct an open trial that includes individuals 50 years and older to assess if a novel version of the Memory Support Intervention improves sleep and circadian functioning, reduces functional impairment, and improves patient memory for treatment.",[147,28,148],"Sleep Disorder","Memory Impairment","2025-11-18",{"date":151,"type":35},"2025-11-24",{"date":153,"type":35},"2024-01-04",{"date":155,"type":22},"2028-07-28",{"name":157,"class":42},"University of California, Berkeley",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":17,"sex":18,"minAge":79,"maxAge":165,"enrollmentInfo":166,"targetDuration":4,"studyType":55,"phases":168,"briefSummary":170,"conditions":171,"keywords":205,"overallStatus":226,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":43},"100565622","phase-1-evaluating-the-efficacy-and-safety-of-prosomnia-sleep-therapy-in-patients-with-sleep-deprivation-and-chronic-insomnia-100565622","NCT06644573","Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia","PSHW","By adhering to the following criteria, the study aims to select a population that can safely undergo the PROSOMNIA Sleep therapy and for whom the therapy is most likely to be beneficial, ensuring the reliability and validity of the study outcomes.\n\nINCLUSION CRITERIA:\n\n1. Age Range: 18-65 years of age Reason: This age range includes adults who are most likely to benefit from the PROSOMNIA Sleep therapy and who can provide informed consent. It also excludes children and older adults who may have different physiological responses or additional health risks.\n2. Diagnosed or Undiagnosed Chronic Insomnia:\n\n   Reason: Included subjects have a consistent pattern of sleep disturbances that PROSOMNIA Sleep Therapy aims to treat.\n3. Diagnosed or Undiagnosed Sleep Deprivation:\n\n   Reason: Includes individuals who are not getting enough sleep quantity, which is a key condition that the PROSOMNIA Sleep Therapy aims to address.\n4. Diagnosed or Undiagnosed REM Sleep Inconsistencies:\n\n   Reason: Includes individuals who are not getting enough sleep quality and those with specific REM sleep phase issues that the PROSOMNIA Sleep Therapy is designed to improve.\n5. Failure to Respond to Conventional Sleep Treatments:\n\n   Reason: Focuses on subjects who have not found relief from existing sleep therapies, ensuring that the study population represents those in need of alternative solutions.\n6. Ability to Provide Informed Consent:\n\nReason: Ensures that participants understand the study and agree to participate voluntarily.\n\nEXCLUSION CRITERIA:\n\n1. Severe Obesity (BMI \\> 40):\n\n   Reason: Severe obesity can increase the risk of complications with anesthesia and may affect sleep patterns in ways that could confound study results.\n2. Cardiovascular Conditions:\n\n   Reason: Patients with significant heart conditions are at higher risk for complications during anesthesia.\n3. Neurological Disorders:\n\n   Reason: These diagnosed conditions and medications such as epilepsy could interfere with sleep patterns and responses to sleep therapy.\n4. Other Health Conditions Contraindicating Anesthesia:\n\n   Reason: Includes any condition that would make the use of anesthesia unsafe.\n5. Greater than ASA II Status:\n\n   Reason: The American Society of Anesthesiologists (ASA) physical status classification system classifies patients based on their pre-anesthesia medical conditions. Excluding those above ASA II ensures that only patients with mild systemic disease are included, to minimize risks.\n6. Current Use of Prohibited Medications:\n\n   Reason: Medications that could interfere with the combined use of anesthesia including, but not limited to sedatives and hypnotics; such as benzodiazepines, Z-drugs and barbiturates.\n7. Pregnancy or Breastfeeding:\n\nReason: Ensures the safety of the fetus or infant, as the effects of the PROSOMNIA Sleep therapy on pregnancy or lactation are unknown.","65 Years",{"count":167,"type":22},100,[169],"PHASE1","This clinical trial aims to evaluate the safety and efficacy of PROSOMNIA Sleep Therapy (PSTx) for individuals suffering from chronic insomnia, sleep deprivation, and REM sleep disorders. Chronic insomnia, characterized by difficulty falling or staying asleep, significantly affects patients and quality of life, mood, and cognitive function. REM sleep disorders, in which the body struggles to enter or maintain restful REM sleep, can worsen these issues. The trial introduces a novel therapy using anesthesia-induced sleep, targeting sleep homeostasis and improving sleep architecture.\n\nObjectives: The primary goals of the trial are to determine:\n\n1. Whether PROSOMNIA Sleep Therapy increases the quality of REM sleep.\n2. Whether PSTx increases the duration of REM and\u002For NREM sleep.\n3. Whether PSTx decreases the time it takes participants to fall asleep (sleep onset latency).\n\nParticipants will receive ONE (1) PROSOMNIA Sleep Therapy session lasting between 60-120 minutes. Each session uses Diprivan\u002FPropofol to induce sleep, and is monitored via an EEG to ensure proper sleep stages, particularly REM sleep.\n\nParticipant Criteria:\n\nInclusion: Adults aged 18-65 with diagnosed or undiagnosed chronic insomnia or sleep deprivation.\n\nExclusion: Patients with severe obesity, significant cardiovascular, neurological, or psychiatric conditions, or those with an ASA status above II.\n\nStudy Design: This trial is non-randomized, single-arm and open-label, with all participants receiving the PSTx. The trial does not include a comparison group, as the focus is on evaluating the immediate, direct effects of the therapy.\n\nParticipants will undergo continuous EEG monitoring during therapy sessions, allowing researchers to track brain activity and sleep stages in real-time. This method ensures that sleep cycles, particularly REM sleep, are optimized for therapeutic benefit.\n\nTherapy Methodology:\n\nPROSOMNIA Sleep Therapy leverages anesthesia to mimic natural sleep patterns and enhance the efficiency of REM sleep. Diprivan\u002FPropofol is used to induce REM sleep, while EEG monitoring tracks and maintains proper sleep architecture throughout the session. The therapy promotes the clearance of adenosine, a compound that builds up during wakefulness and drives the need for sleep. Adenosine is cleared during REM sleep, reducing sleep pressure and improving cognitive function.\n\nOutcome Measures:\n\nPrimary Outcomes: Researchers will measure the increase in REM sleep duration, improvement in sleep quality (via self-reported questionnaires), and a reduction in sleep onset latency.\n\nSecondary Outcomes: These include changes in mood, cognitive function, and blood serum uric acid levels. Patient-reported outcomes will also be tracked through tools like the PROSOMNIA Sleep Quiz, which is specifically designed for PSTx.\n\nSignificance: Chronic insomnia and REM sleep disorders affect millions globally, leading to cognitive impairment, mood disturbances, and poor overall health. Traditional treatments, including pharmacological approaches and Cognitive Behavioral Therapy for Insomnia (CBT-I), often provide suboptimal results for many individuals. PSTx offers a novel, therapeutic approach to restoring sleep balance and enhancing the overall quality of sleep, particularly for those who have not responded to conventional treatments.\n\nStudy Process:\n\nRecruitment and Baseline Assessments: Participants undergo a comprehensive sleep assessment, including sleep questionnaires and polysomnography, to establish a baseline for sleep quality and duration. Blood serum uric acid levels will also be measured to track any biochemical changes due to therapy.\n\nTherapy Sessions: Only one (1) PROSOMNIA Sleep Therapy session will be administered, with the session lasting between 60-120 minutes. Diprivan\u002FPropofol is used to induce sleep, and EEG will monitor brain activity to ensure the proper balance of sleep stages.\n\nPost-Therapy Follow-up: Follow-up assessments will occur at 24 hours, 7 days, and 30 days post-treatment. Researchers will analyze the therapy effects on REM sleep, mood, cognitive function, and other health indicators.\n\nPotential Implications: If successful, this trial could revolutionize how we treat sleep disorders by targeting the underlying mechanisms of sleep pressure and REM sleep disruption. PROSOMNIA Sleep Therapy may offer a safe, effective, and immediate alternative for patients who have exhausted other treatment options.\n\nKey Concepts:\n\nHomeostatic sleep drive, (Process S), caused by adenosine buildup during wakefulness, is disrupted by chronic insomnia. This impacts cognitive function health and recovery. Anesthesia-induced REM sleep via PSTx helps regulate this homeostatic sleep stage, offering deeper and more restorative sleep compared to other sleep therapies. The study uses statistical methods like ANOVA and Chi-square to measure outcomes.",[172,119,173,174,175,176,177,178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,115,28,194,195,196,197,113,198,199,200,201,202,203,204],"Chronic Insomnia","REM Behavior Disorder","REM Sleep Behavior Disorder","REM Sleep Measurement","Insomnia","Insomnia Related to Specified Disorder","Insomnia Due to Other Mental Disorder","Insomnia Comorbid to Psychiatric Disorder","Insomnia Due to Anxiety and Fear","Insomnia Related to Another Mental Condition","Insomnia Disorders","Idiopathic Hypersomnia","Sleep Disorders, Circadian Rhythm","Post Trauma Nightmares","PTSD - Post Traumatic Stress Disorder","Sleep Quality","Anesthesia","Anxiety","Depression","Mental Health","Alzheimer Disease or Associated Disorder","Parkinsons","PTSD","Post-Traumatic","Post-Traumatic Stress Disorder Complex","Military Combat Stress Reaction","Military Activity","Veterans","Shift Work Sleep Disorder","Menopause Related Conditions","Pain","Cancer Pain","Athletes",[206,207,208,209,210,211,212,213,214,215,216,217,218,219,220,221,222,223,176,119,224,183,225,194,191,189,190],"SLEEP","PROSOMNIA Sleep","PROSOMNIA Sleep Therapy","PSTx","PROSOMNIA","Anesthesia Sleep","REM Sleep","REM Sleep Therapy","PROSOMNIA Sleep Health","PROSOMNIA Sleep Wellness","PROSOMNIA Sleep Treatment","Nyree","Nyree Penn","Propofol","Propofol Sleep","Diprivan","Diprivan Sleep","PROSOMNIA Sleep Health and Wellness","IH","Sleep Debt","NOT_YET_RECRUITING","2025-05-27",{"date":229,"type":35},"2025-05-28",{"date":231,"type":22},"2025-11-01",{"date":233,"type":22},"2026-05-01",{"name":218,"class":235},"INDUSTRY",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":18,"minAge":79,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":55,"phases":245,"briefSummary":246,"conditions":247,"keywords":251,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":261,"locationsCount":43},"100586978","the-effects-of-naturalistic-light-on-post-stroke-complications-related-brain-areas-in-stroke-patients-during-admission-for-rehabilitation-100586978","NCT06922409","The Effects of Naturalistic Light on Post Stroke Complications Related Brain Areas in Stroke Patients During Admission for Rehabilitation.","The Effects of Naturalistic Light on Post Stroke Complications Related Brain Areas in Stroke Patients During Admission for Rehabilitation","Inclusion Criteria:\n\n* Patients scoring moderate-severe fatigue and\u002For depression OR NO fatigue and\u002For depressione which are evaluated as candidates for the rehabilitation unit.\n\nExclusion Criteria:\n\n* GCS \\\u003C 15\n* No functioning nervus opticus or retina in both eyes\n* Unable to open both eyes\n* Non communicating patients e.g. severe aphasia (incompetent patients)\n* Unable to cooperate to the physical examinations\n* Less than 10 days of hospitalization in the rehabilitation department\n* Claustrophobia\n* If the sub investigator finds the study participant unfit to conduct the investigations",{"count":244,"type":22},45,[57],"Background:\n\nLight is the most important regulator of circadian rhythm. Naturalistic light, which contains the spectrum of sunlight throughout the day, has been shown to have a positive impact on mental states such as depression and fatigue in stroke and other diseases requiring long-term hospitalization.\n\nDepression and fatigue are very common complications after stroke, with a frequency of 30% and 85%, respectively. Both are significantly related to reduced quality of life and early death. Both the causes and pathophysiology behind these complications are unknown, but it is assumed that disturbances (inflammation and cell death) in brain areas and brain networks related to arousal, sleep, circadian rhythm, and the frontal lobe play a role.\n\nThe hypothesis is that it is possible to detect changes in brain networks related to depression and fatigue by MRI, and that naturalistic light will affect these changes.\n\nMethod:\n\nStroke patients requiring a minimum of 10 days of rehabilitation are transferred to a neurorehabilitation unit with naturalistic lighting.\n\nExamination:\n\nValidated tests for fatigue, depression, sleep and cognitive functions.\n\nPathophysiological studies:\n\n* MRI focusing on cerebral blood flow, metabolism, and cerebral networks.\n* Spinal fluid analyses for hormones and markers involved in immunological response as well as wakefulness\u002Farousal and depression.\n* Sleep assessments.",[248,249,28,250],"Post Stroke Depression","Post Stroke Fatigue","Stroke",[252,250,248,249,253,254],"circadian rhythm disruption","Light therapy","Circadian Light","2025-04-10",{"date":257,"type":35},"2025-04-15",{"date":255,"type":35},{"date":260,"type":22},"2030-01-01",{"name":262,"class":42},"Rigshospitalet, Denmark"]